DE69929361D1 - Botulinumtoxine zur verstärkung der wundheilung - Google Patents
Botulinumtoxine zur verstärkung der wundheilungInfo
- Publication number
- DE69929361D1 DE69929361D1 DE69929361T DE69929361T DE69929361D1 DE 69929361 D1 DE69929361 D1 DE 69929361D1 DE 69929361 T DE69929361 T DE 69929361T DE 69929361 T DE69929361 T DE 69929361T DE 69929361 D1 DE69929361 D1 DE 69929361D1
- Authority
- DE
- Germany
- Prior art keywords
- toxines
- botulinum
- reinforcement
- wound healing
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10568898P | 1998-10-27 | 1998-10-27 | |
US105688P | 1998-10-27 | ||
PCT/US1999/024182 WO2000024419A1 (en) | 1998-10-27 | 1999-10-15 | Methods for enhancing wound healing |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69929361D1 true DE69929361D1 (de) | 2006-03-30 |
DE69929361T2 DE69929361T2 (de) | 2006-09-14 |
Family
ID=22307238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69929361T Expired - Lifetime DE69929361T2 (de) | 1998-10-27 | 1999-10-15 | Botulinumtoxine zur verstärkung der wundheilung |
Country Status (12)
Country | Link |
---|---|
US (3) | US6447787B1 (de) |
EP (1) | EP1128844B1 (de) |
JP (1) | JP2002528421A (de) |
KR (1) | KR20010089347A (de) |
CN (1) | CN1324246A (de) |
AT (1) | ATE314859T1 (de) |
AU (1) | AU1706400A (de) |
BR (1) | BR9914891A (de) |
CA (1) | CA2347828A1 (de) |
DE (1) | DE69929361T2 (de) |
MX (1) | MXPA01004254A (de) |
WO (1) | WO2000024419A1 (de) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6276072B1 (en) * | 1997-07-10 | 2001-08-21 | Applied Materials, Inc. | Method and apparatus for heating and cooling substrates |
CA2347828A1 (en) * | 1998-10-27 | 2000-05-04 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
WO2002000172A2 (en) * | 2000-06-28 | 2002-01-03 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
CA2416289C (en) | 2000-07-21 | 2012-12-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
AU2002355730B2 (en) * | 2001-07-27 | 2007-09-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
EP1443932B1 (de) * | 2001-11-15 | 2012-12-26 | Micro Algae Corporation | Pharmazeutische zusammensetzungen mit 3,4-propinoperhydropurinen und ihre verwendung zur blockierung der neuronalen übertragung |
US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
EP1594523B1 (de) * | 2002-12-20 | 2009-03-25 | Botulinum Toxin Research Associates, Inc. | Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
EP1599220B1 (de) * | 2003-03-06 | 2013-07-17 | Botulinum Toxin Research Associates, Inc. | Auswahl von patienten mit erhöhtem ansprechen auf botulinustoxin |
US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CA3031270A1 (en) | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
PT1729821E (pt) * | 2004-03-03 | 2013-10-23 | Revance Therapeutics Inc | Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
AU2005244096B2 (en) | 2004-05-07 | 2011-03-17 | Algenis Spa | Transdermal administration of phycotoxins |
CA2821239C (en) * | 2004-05-07 | 2016-04-12 | Phytotox Limited | Phycotoxins and uses thereof |
US6991789B2 (en) * | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
EP1799254A1 (de) * | 2004-09-27 | 2007-06-27 | Merz Pharma GmbH & Co.KGaA | Clostridium-neurotoxine zur verwendung bei der gewebeheilung |
US7897147B2 (en) * | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
GB0427642D0 (en) * | 2004-12-16 | 2005-01-19 | Renovo Ltd | Information collection system |
FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
US7749515B2 (en) * | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
EP1861112A4 (de) * | 2005-03-03 | 2009-07-22 | Revance Therapeutics Inc | Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulinumtoxinen |
CA2606315A1 (en) * | 2005-05-05 | 2006-11-09 | Phytotox Limited | Use of phycotoxins in veterinary applications |
US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
US20060269574A1 (en) * | 2005-05-31 | 2006-11-30 | De Beer Johann F | Method of repairing tendons by surgery |
KR101423272B1 (ko) * | 2005-11-17 | 2014-07-30 | 레반스 테라퓨틱스, 아이엔씨. | 감소된 비-독소 단백질을 갖는 보툴리눔 독소의 국소 적용및 경피 전달을 위한 조성물 및 방법 |
US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
US20070178121A1 (en) * | 2006-01-27 | 2007-08-02 | Allergan, Inc. | Methods for enhancing skin treatments |
US20070178666A1 (en) * | 2006-01-31 | 2007-08-02 | Stats Chippac Ltd. | Integrated circuit system with waferscale spacer system |
US7414310B2 (en) * | 2006-02-02 | 2008-08-19 | Stats Chippac Ltd. | Waferscale package system |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
EP2109363A4 (de) * | 2006-12-29 | 2014-07-09 | Revance Therapeutics Inc | Transportmoleküle mit umkehrsequenz-hiv-tat-polypeptiden |
CN101616682A (zh) * | 2006-12-29 | 2009-12-30 | 雷文斯治疗公司 | 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法 |
CN101842107B (zh) | 2007-07-26 | 2014-04-23 | 雷文斯治疗公司 | 抗微生物肽,组合物和使用方法 |
US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
US20100028385A1 (en) * | 2008-08-04 | 2010-02-04 | Allergan, Inc. | Treatment of excess cerumen secretion |
AU2009298411B2 (en) | 2008-10-02 | 2013-06-06 | Mylan Inc. | Method of making a multilayer adhesive laminate |
CA2745657C (en) | 2008-12-04 | 2022-06-21 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
US20100184685A1 (en) * | 2009-01-19 | 2010-07-22 | Zavala Jr Gerardo | Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein |
EP2480250B1 (de) | 2009-09-24 | 2014-04-16 | Allergan, Inc. | Zusammensetzungen Botulinumtoxin A oder B enthaltend zur Verwendung bei der Behandlung der Osteoporose |
US20130123647A1 (en) | 2011-05-03 | 2013-05-16 | The Research Foundation Of State University Of New York | Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections |
US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
KR101135486B1 (ko) * | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
CN103501802B (zh) * | 2011-06-27 | 2016-03-16 | 金相德 | 皮肤疤痕治疗用药物组合物及利用其的皮肤疤痕治疗方法 |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
WO2014066916A2 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
WO2015126527A1 (en) * | 2014-02-18 | 2015-08-27 | Kaufman-Janette Joely | Botulinum neurotoxin for use in the prophylactic treatment of cutaneous wounds |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
SG11201701619TA (en) * | 2014-09-02 | 2017-03-30 | American Silver Llc | Botulinum toxin and colloidal silver particles |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
US10272024B1 (en) | 2016-11-28 | 2019-04-30 | Muhammad Mirza | Methods for administration of cosmetic and medical agents |
EP3470054B1 (de) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Mikrostrukturformulierungstechniken für botulinumtoxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
US20190183987A1 (en) * | 2017-12-18 | 2019-06-20 | Bonti, Inc. | Neurotoxins for use in minimizing scarring |
EP3825689A3 (de) | 2018-11-29 | 2021-09-15 | Hugel Inc. | Zellbasiertes verfahren zur bestimmung der aktivität von botulinumtoxin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966934A (en) | 1971-12-08 | 1976-06-29 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
US3957996A (en) | 1971-12-08 | 1976-05-18 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic compositions |
US4029794A (en) | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition |
US4029793A (en) | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
US4080448A (en) | 1974-11-13 | 1978-03-21 | Mirsky Louis H | Method of treating cellular stress |
JPS5594319A (en) | 1979-01-09 | 1980-07-17 | Yoshio Otaka | Drug for external use consisting of liver oil of swellfish |
ES2194025T3 (es) | 1993-06-10 | 2003-11-16 | Allergan Inc | Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares. |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
DE69620888T2 (de) | 1996-11-27 | 2002-08-14 | William J Binder | Neurotoxine zur Behandlung von Hauterkrankungen bei Säugetieren |
AU6883798A (en) * | 1997-04-02 | 1998-10-22 | Regents Of The University Of California, The | Method of anesthesia |
CA2347828A1 (en) * | 1998-10-27 | 2000-05-04 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
-
1999
- 1999-10-15 CA CA002347828A patent/CA2347828A1/en not_active Abandoned
- 1999-10-15 EP EP99960130A patent/EP1128844B1/de not_active Expired - Lifetime
- 1999-10-15 US US09/807,793 patent/US6447787B1/en not_active Expired - Lifetime
- 1999-10-15 AT AT99960130T patent/ATE314859T1/de not_active IP Right Cessation
- 1999-10-15 BR BR9914891-9A patent/BR9914891A/pt not_active IP Right Cessation
- 1999-10-15 WO PCT/US1999/024182 patent/WO2000024419A1/en active IP Right Grant
- 1999-10-15 DE DE69929361T patent/DE69929361T2/de not_active Expired - Lifetime
- 1999-10-15 CN CN99812622A patent/CN1324246A/zh active Pending
- 1999-10-15 JP JP2000578027A patent/JP2002528421A/ja active Pending
- 1999-10-15 AU AU17064/00A patent/AU1706400A/en not_active Abandoned
- 1999-10-15 MX MXPA01004254A patent/MXPA01004254A/es unknown
- 1999-10-15 KR KR1020017005176A patent/KR20010089347A/ko not_active Application Discontinuation
-
2001
- 2001-11-26 US US09/995,022 patent/US20030036502A1/en not_active Abandoned
-
2005
- 2005-02-18 US US11/061,299 patent/US20060039930A2/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69929361T2 (de) | 2006-09-14 |
EP1128844B1 (de) | 2006-01-04 |
KR20010089347A (ko) | 2001-10-06 |
BR9914891A (pt) | 2001-07-17 |
US20060039930A2 (en) | 2006-02-23 |
EP1128844A4 (de) | 2002-06-12 |
MXPA01004254A (es) | 2002-04-24 |
CN1324246A (zh) | 2001-11-28 |
WO2000024419A9 (en) | 2001-09-20 |
US20050175637A1 (en) | 2005-08-11 |
EP1128844A1 (de) | 2001-09-05 |
US6447787B1 (en) | 2002-09-10 |
US20030036502A1 (en) | 2003-02-20 |
CA2347828A1 (en) | 2000-05-04 |
AU1706400A (en) | 2000-05-15 |
ATE314859T1 (de) | 2006-02-15 |
WO2000024419A1 (en) | 2000-05-04 |
JP2002528421A (ja) | 2002-09-03 |
WO2000024419A8 (en) | 2001-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69929361D1 (de) | Botulinumtoxine zur verstärkung der wundheilung | |
PT938326E (pt) | Fosfopeptidos de sintese para o tratamento de doencas dos ossos | |
DE60142839D1 (de) | Botulinum Toxin zur Behandlung von akuten Verletzungen der Skelettmuskeln | |
ATE302599T1 (de) | Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege | |
ATE395022T1 (de) | Zusammensetzung und verfahren zur beschleunigung von wunden- und brandheilung | |
ATE420947T1 (de) | Gewebeimplant zur wiederherstellung von knorpelgewebe | |
BR0304601A (pt) | Curativo de ferimento hemostático contendo polissacarìdeos modificados por aldeìdo | |
ES2166783T3 (es) | Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii. | |
ATE411018T1 (de) | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) | |
BR0213100A (pt) | Combinações para o tratamento de distúrbios imuniinflamatórios | |
DE69813200D1 (de) | Verbesserung der wundheilung mit cm101/gbs-toxin | |
ATE275580T1 (de) | Verfahren zur induktion der herstellung von wachstumsfaktoren | |
DE60118769D1 (de) | Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten | |
ATE246924T1 (de) | Neue therapeutische verwendung von nicergoline | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
NO984197L (no) | FremgangsmÕte for behandling av autisme | |
ATE222501T1 (de) | Tissue-faktor zur beeinflussung von gefässbildung | |
DE60143278D1 (de) | Verfahren zur Vorbeugung oder Behandlung von Diabetes | |
NO984196D0 (no) | Fremgangsmåte for behandling av stoffmisbruk | |
ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
NO984198L (no) | FremgangsmÕte for behandling av aggresjon | |
RU2153372C2 (ru) | Способ лимфогенной детоксикации | |
ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
NO984190L (no) | FremgangsmÕte for behandling av insomnia | |
UA30556A (uk) | Спосіб модуляції гоєння ран |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |